リルピビリン塩酸塩
リルピビリン塩酸塩 物理性質
- 貯蔵温度 :
- Store at -20°C
- 溶解性:
- DMSO:50.0(Max Conc. mg/mL);136.46(Max Conc. mM)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
リルピビリン塩酸塩 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
リルピビリン塩酸塩 化学特性,用途語,生産方法
効能
抗ウイルス薬, 逆転写酵素阻害薬
商品名
エジュラント (ヤンセンファーマ)
使用
Rilpivirine Hydrochloride was shown to be able to treat and or prevent immunodeficiency virus-1. It also has uses for anti-viral therapy
定義
ChEBI: A hydrochloride obtained by reaction of rilpivirine with one equivalent of hydrochloric acid. Used for treatment of HIV.
臨床応用
Rilpivirine hydrochloride (Edurant), a non-nucleoside reverse
transcriptase inhibitor (NNRTI), received its approval both from
the U.S. FDA and E.U. EMA in 2011 for the treatment of HIV-1 infection in treatment-na?ve adult patients. It was discovered and
developed by Janssen Pharmaceuticals and its subsidiary Tibotec
Pharmaceuticals. As a second generation NNRTI, rilpivirine hydrochloride
displayed higher potency and longer half-life with a 25 mg
once a day dose, compared to existing NNRTIs, such as the 200 mg
BID of efavirenze (Sustiva). In late 2011, the fixed-dose
combination products of rilpivirine hydrochloride with two
nucleoside reverse transcriptase inhibitor (RTIs) emtricitabine and tenofovir disoproxil fumarate, co-developed by Gilead Science
and Tibotec, were also approved both by the FDA and EMA under
brand names Complera® and Eviplera®, respectively.
リルピビリン塩酸塩 上流と下流の製品情報
原材料
準備製品
リルピビリン塩酸塩 生産企業
Global( 76)Suppliers
700361-47-3(リルピビリン塩酸塩)キーワード:
- 700361-47-3
- RILPIVIRINE HCL
- Rilpivirine-d6 HCl
- Rilpivirine HCl (TMC278
- TMC 278. trade name Edurant
- Rilpivirine Hydrochloride
- Ripivirine Hydrochloride
- リルピビリン塩酸塩
- リルピビリン塩酸塩 (JAN)